Back to Search
Start Over
A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale
- Source :
- Mucci, A, Vignapiano, A, Bitter, I, Austin, S F, Delouche, C, Dollfus, S, Erfurth, A, Fleischhacker, W W, Giordano, G M, Gladyshev, I, Glenthøj, B, Gütter, K, Hofer, A, Hubeňák, J, Kaiser, S, Libiger, J, Melle, I, Nielsen, M Ø, Papsuev, O, Rybakowski, J K, Sachs, G, Üçok, A, Wojciak, P & Galderisi, S 2019, ' A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale ', European Neuropsychopharmacology, vol. 29, no. 8, pp. 947-959 . https://doi.org/10.1016/j.euroneuro.2019.05.006, European Neuropsychopharmacology, Vol. 29, No 8 (2019) pp. 947-959
- Publication Year :
- 2019
-
Abstract
- Negative symptoms represent an unmet need of treatment in schizophrenia. Although a consensus exists on negative symptom construct, and second generation assessment instruments reflecting the consensus are available, studies still rely upon old assessment instruments, that do not reflect recent conceptualizations and might limit progress in the search for effective treatments. This is often the case in the European context, where one of the challenges encountered in designing large studies is the availability of validated instruments in the many languages of the continent. To address this challenge and promote sound research on negative symptoms in Europe, the ECNP Schizophrenia Network coordinated a large multicenter, multinational validation study of the Brief Negative Symptom Scale (BNSS). Clinically-stable subjects with schizophrenia (SCZ, N = 249) were recruited from 10 European Countries. Apart from BNSS, subjects were administered the Positive and Negative Syndrome Scale (PANSS) and standardized instruments for depression, extrapyramidal symptoms and psychosocial functioning. Results showed an excellent internal consistency, convergent and discriminant validity of BNSS and replicated a 5 factor-model. A larger number of subjects with predominant negative symptoms, i.e. the target population for clinical trials, was identified by using the BNSS compared to the PANSS. Regression analysis showed that BNSS-avolition, a key negative symptom poorly assessed by PANSS, explained 23.9% of psychosocial functioning, while no combination of the PANSS core negative symptoms showed the same impact on functioning. The study demonstrated that BNSS has substantial advantages with respect to PANSS for the identification of the avolition domain and subjects with predominant negative symptoms. (C) 2019 The Author(s). Published by Elsevier B.V.
- Subjects :
- Adult
Male
BNSS
Negative symptom
Context (language use)
PANSS-negative subscale
03 medical and health sciences
ddc:616.89
0302 clinical medicine
Extrapyramidal symptoms
medicine
Humans
Pharmacology (medical)
Avolition
Biological Psychiatry
Depression (differential diagnoses)
Pharmacology
Psychiatric Status Rating Scales
Positive and Negative Syndrome Scale
business.industry
Discriminant validity
Functional outcome
medicine.disease
030227 psychiatry
Europe
Psychiatry and Mental health
Neurology
Schizophrenia
Female
Schizophrenic Psychology
Neurology (clinical)
Negative symptoms
medicine.symptom
business
Psychosocial
030217 neurology & neurosurgery
Clinical psychology
Subjects
Details
- ISSN :
- 18737862 and 0924977X
- Volume :
- 29
- Issue :
- 8
- Database :
- OpenAIRE
- Journal :
- European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
- Accession number :
- edsair.doi.dedup.....9541ee1f224aeff1afcf6d32beae72f8